NCT03211117View on ClinicalTrials.gov

Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

August 14, 2017

Primary Completion Date

February 12, 2018

Study Completion Date

March 28, 2019

Conditions
Thyroid Gland Undifferentiated (Anaplastic) Carcinoma
Interventions
DRUG

Docetaxel

Given IV

DRUG

Doxorubicin Hydrochloride

Given IV

RADIATION

Intensity-Modulated Radiation Therapy

Undergo IMRT

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pembrolizumab

Given IV

PROCEDURE

Therapeutic Conventional Surgery

Undergo surgery

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER